Cerebral palsy medical therapy

Revision as of 00:52, 6 October 2017 by Ahmed Younes (talk | contribs)
Jump to navigation Jump to search

Cerebral palsy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cerebral Palsy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cerebral palsy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cerebral palsy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cerebral palsy medical therapy

CDC on Cerebral palsy medical therapy

Cerebral palsy medical therapy in the news

Blogs on Cerebral palsy medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Cerebral palsy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Medical Therapy

Botulinum toxin

  • Botulinum toxin acts on the neuromuscular junction preventing the release of acetylcholine.
  • It has a relaxant effect on the muscles undergoing contractures.
  • Primarily used if there are contractures causing deformity or jeopardizing the nearby joints.
  • The injections cause temporary improvement in the function of the affected limbs.
  • Botulinum toxin injections may decrease the joint and bone deformities resulting from the contractures especially if combined with casting.
  • Children under four years in the early stages of contractures are the most category of patients to benefit from botulinum toxin.
  • Botulinum toxin delays the need for a surgery and decreases the magnitude of intervention.
  • The effect is temporary and the injection has to be repeated every three to six months.
  • Generalized weakness due to the global effect of the drug was reported.
  • The dose of abobotulinum toxin A is 20-30 unit/kg divided between the injected limbs. The dose should not exceed 1000 units.

{{#ev:youtube|l7l0csoCQkM}}

Intrathecal baclofen

  • Baclofen is administered through a pump into the subarachnoid space.
  • It can achieve higher CSF levels of the drug with less side effects.
  • It acts by blocking the I-a sensory afferents.
  • It is indicated in the patients with the highest of spasticity that is causing dysfuction and pain not responding to the more conventional methods of treatment.
  • It carries more risk of complications than other non interventional lines of treatment.
  • The pump must refilled every month together with assessment for the occurrence of complications.
  • Complications such as hypotonia and confusion occur in about half of the patients.
  • The dose is adjusted by the physician according to the response and the development of side effects.

{{#ev:youtube|IeS-Wr4izo4}}

Oral muscle relaxants

Benzodiazepines

  • Binds to GABA receptors and causes presynaptic inhibition of the neurotransmission.
  • Most useful for acute cases of severe spasticity.
  • Due to its muscle relaxing effect, it can aggravate the swallowing difficulties and cause aspiration.

Baclofen

  • GABA analogue and causes presynaptic inhibition of neurotransmission.
  • Much less effective than intrathecal baclofen.

Dantrolene

  • Direct muscle relaxant by inhibiting the release of Ca+2 from the sarcoplasmic reticulum.
  • Used only in the short term for treatment of acute cases of severe hypertonicity.

References

Template:WH Template:WS